Oncology firm Elekta has received CE Mark approval to sell its Integrity R1.1 treatment system in the European Union.
Integrity supports a range of delivery techniques, including intensity modulated radiation therapy, volumetric modulated arc therapy, and stereotactic applications.
The device combines a three-tier safety system with continuously variable dose rate and interdigitation capabilities for the company's MLCi2 multileaf collimator. The first safety tier records and verifies the prescription received from the MOSAIQ oncology information system and checks that all linac parameters are set correctly. It then checks and controls multileaf collimator leaves, gantry, collimator, and dose delivery throughout beam delivery. This guarantees that all parameters are in the correct position and the prescribed dose is being delivered. A third tier, Guardian, supervises the proper operation of the other two tiers, and if a discrepancy occurs, stops the treatment.
